Last reviewed · How we verify
NCT03572491
Preventive Effectiveness, Safety and Immunogenicity of a Allantoic Split Inactivated Seasonal Influenza Vaccine
Phase 3 trial testing influenza vaccine in Human Influenza in 2,000 participants. Completed in 21 May 2018.
21 May 2018
Quick facts
| Lead sponsor | Research Institute for Biological Safety Problems |
|---|---|
| Phase | Phase 3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 2,000 |
| Start date | 18 September 2017 |
| Primary completion | 21 May 2018 |
| Estimated completion | 21 May 2018 |
| Sites | 1 location across Kazakhstan |
Drugs / interventions tested
- influenza vaccine — full drug profile →
Conditions studied
- Human Influenza — all drugs for Human Influenza →
Sponsor
Research Institute for Biological Safety Problems
Who can join
18 and older, any sex, with Human Influenza. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study is Multicenter, phase 3, Open-Label trial that explored the preventive effectiveness, safety and immunogenicity of single dose a allantoic split inactivated seasonal influenza vaccine in healthy adults.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03572491
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of influenza vaccine
Trials testing the same drug.
- NCT06091410 — Immunogenicity of Concomitant Administration of COVID-19 Vaccines With Influenza Vaccines · Phase 4 · unknown
- NCT04579822 — Maternal and Fetal Outcomes Following Influenza Vaccination in Pregnancy · unknown
- NCT04091880 — Evaluation of the Safety and Immunogenicity of Simultaneously Administration of EV71 Vaccine and Influenza Vaccine · Phase 4 · completed
- NCT03323112 — Immune Responses in Health Care Personnel · recruiting
Other recruiting trials for Human Influenza
Currently open trials in the same condition.
- NCT04487041 — Tfh Dysfunction in HIV and Aging · Phase 4 · recruiting
Other Research Institute for Biological Safety Problems trials
Trials by the same sponsor.
- NCT04930003 — Reactogenicity, Safety and Immunogenicity of QazCoVac-P COVID-19 Vaccine · Phase 1, PHASE2 · completed
- NCT04691908 — Immunogenicity, Efficacy and Safety of QazCovid-in® COVID-19 Vaccine · Phase 3 · completed
- NCT04530357 — Reactogenicity, Safety and Immunogenicity of QazCovid-in® COVID-19 Vaccine · Phase 1, PHASE2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03572491 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Research Institute for Biological Safety Problems
- Last refreshed: 28 June 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03572491.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing